I am a general pediatrician in Memorial Sloan Kettering’s Pediatric Long-Term Follow-Up Program. We provide comprehensive risk-based screening and follow-up care to children and young adults who are survivors of childhood cancers. We aim to detect and treat late effects that arise as a result of prior therapies while also emphasizing patient education and preventive counseling.
My current research focuses on medical and quality-of-life outcomes in survivors of retinoblastoma, a rare tumor of the eye. I am also interested in long-term outcomes and optimal screening practices in patients who have received high-risk therapies, such as chest radiation and total body irradiation.
After completing my pediatric residency at NYP-Cornell, I served as Pediatric Chief Resident here at Memorial Sloan Kettering. During that year, I coordinated and helped supervise residents rotating through our inpatient pediatric service. I was fortunate to learn a great deal about the inpatient management of many of the cancers for which our patients have been treated. It is gratifying to see these same patients after the completion of their treatment in our Long-Term Follow-Up clinic.
- Clinical Expertise: Pediatric Survivorship: long-term care of survivors of childhood cancers
- Languages Spoken: English
- Education: MD, Albert Einstein College of Medicine
- Residencies: NewYork-Presbyterian Hospital/Weill Cornell Medical Center; Memorial Sloan Kettering Cancer Center
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Pediatrics
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.